GRIP Molecular Technologies

GRIP Molecular Technologies is developing a next-generation diagnostic platform that combines the precision of molecular testing with the simplicity and speed of lateral flow assays. Its core innovation is a CRISPR protease engine that detects pathogen RNA and amplifies signal in minutes at room temperature, eliminating the need for complex nucleic acid pre-amplification steps. The platform is designed to be pathogen-agnostic and adaptable to various sample types and readout formats, targeting the significant unmet need for fast, accurate, and affordable diagnostics in point-of-need settings. With a focus on a multi-billion dollar market for STI, UTI, and URI testing, GRIP aims to close the gap between centralized lab testing and decentralized clinical demand.

CRISPR protease-based diagnostic platform that detects pathogen RNA and uses catalytic signal amplification on protein substrates, enabling rapid, room-temperature, amplification-free molecular tests adaptable to lateral flow, electrochemical, and colorimetric readouts.

GRIP competes in the rapidly evolving CRISPR diagnostics space against companies using Cas12/Cas13 nucleases (e.g., Mammoth, Sherlock). Its differentiation hinges on a protease-based system promising simpler workflow and nuclease-resistant reporters. It also competes broadly with traditional rapid test makers and companies developing other isothermal amplification-based POC molecular tests.